Harmony Biosciences Says New Data Supports Neurology Pipeline
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY ) shares closed higher by around 8% on Tuesday following the company's announcement of record revenue for the second quarter of 2026. The neurological disease-focused pharma company reported second quarter earnings of $1.28 per share, beating the consensus of 94 cents. R